Introduction: Alloimmunization to red blood cell antigens is one of the main complications of transfusion therapy. The appropriate pre-transfusion tests are necessary in order to minimize hemolytic reactions related to RBC alloantibodies. The aim of this study was to determine the frequency and specificity of RBC alloantibodies detected during pre-transfusion tests in addition to risk factors of alloimmunization in the hospitalized population in Tehran, Iran.
Materials and Methods: In this retrospective study, the characteristics and type of alloantibodies in 31 alloimminized patients among 6029 hospitalized patients of Imam Khomeini general hospital were examined during September 2016 to January 2017.
Results: The RBC alloantibody prevalence was 0.5% with the male: female ratio of 1:5.2. The most frequent antibodies were anti-D (30%), anti-E (24%) and anti-K (12%). Female sex, age, history of transfusion and pregnancy or abortion history were associated with alloimmunization.
Conclusion:The alloimmunization rate were relatively low in hospitalized patients in this study. Female sex, age, history of transfusion and pregnancy sound to be the risk factors of alloimmnization.
Gharehbaghian A, Ghezelbash B, Aghazade S, Hojjati MT. Evaluation of alloimmunization rate and necessity of blood type and screening test among patients candidate for elective surgery. International journal of hematology-oncology and stem cell research. 2014;8(1):1.
Caamaño J, Musante E, Contreras M, Ulloa H, Reyes C, Inaipil V, et al. Frequency and specificity of red blood cell alloimmunization in chilean transfused patients. Transfusion Medicine and Hemotherapy. 2015;42(1):4-7.
Reyhaneh K, Ahmad G, Gharib K, Vida V, Raheleh K, Mehdi TN. Frequency & specificity of RBC alloantibodies in patients due for surgery in Iran. The Indian journal of medical research. 2013;138(2):252.
Tormey CA, Fisk J, Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion. 2008;48(10):2069-76.
Solh Z, Athale U, Arnold D, Cook R, Foley R, Heddle N. Transfusion‐related alloimmunization in children: epidemiology and effects of chemotherapy. Vox sanguinis. 2016;111(3):299-307.
Natukunda B, Schonewille H, Van De Watering L, Brand A. Prevalence and specificities of red blood cell alloantibodies in transfused Ugandans with different diseases. Vox sanguinis. 2010;98(2):167-71.
Zaidi U, Borhany M, Ansari S, Parveen S, Boota S, Shamim I, et al. Red cell alloimmunisation in regularly transfused beta thalassemia patients in Pakistan. Transfusion Medicine. 2015;25(2):106-10.
Wang LY, Liang DC, Liu HC, Chang FC, Wang CL, Chan YS, et al. Alloimmunization among patients with transfusion‐dependent thalassemia in Taiwan. Transfusion Medicine. 2006;16(3):200-3.
Azarkeivan A, Ansari S, Ahmadi MH, Hajibeigy B, Maghsudlu M, Nasizadeh S, et al. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatric hematology and oncology. 2011;28(6):479-85.
Amin M, Gholamhossein T, Majid N, Marziyeh H, Narges S, Akbar D. Prevalence of alloimmunization against RBC antigens in thalassemia major patients in South East of Iran. J Blood Disorders Transf. 2013;4(147):2.
Zheng Y, Maitta R. Alloimmunisation rates of sickle cell disease patients in the United States differ from those in other geographical regions. Transfusion Medicine. 2016;26(3):225-30.
Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002;42(1):37-43.
Allali S, Peyrard T, Amiranoff D, Cohen JF, Chalumeau M, Brousse V, et al. Prevalence and risk factors for red blood cell alloimmunization in 175 children with sickle cell disease in a French university hospital reference centre. British Journal of Haematology. 2017;177(4):641-7.
Stack G, Tormey CA. Detection rate of blood group alloimmunization based on real‐world testing practices and kinetics of antibody induction and evanescence. Transfusion. 2016;56(11):2662-7.
Schonewille H, Haak HL, Van Zijl AM. RBC antibody persistence. Transfusion. 2000;40(9):1127-31.
Nadarajan S, Hlaing A, Maung T, Jeyajoti I, Kyu T, Ranjana K, et al. Incidence of red cell alloantibodies in a multi-ethnic hospital patient population. Vox Sanguinis. 2007;93:63-4.
Wang Q, Yang Q, Bai Y, Zhang C, Diao Y, Fang D. Frequency of RBC alloantibodies in Chinese surgical patients. Transfusion Medicine and Hemotherapy. 2012;39(4):283-6.
Xu P, Li Y, Yu H. Prevalence, specificity and risk of red blood cell alloantibodies among hospitalised Hubei Han Chinese patients. Blood transfusion. 2014;12(1):56.
Bauer MP, Wiersum‐Osselton J, Schipperus M, Vandenbroucke JP, Briët E. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion. 2007;47(11):2066-71.
Abdelrazik AM, Elshafie SM, El Said MN, Ezzat Ahmed GM, Al‐Gamil AKA, El Nahhas MGM, et al. Study of red blood cell alloimmunization risk factors in multiply transfused thalassemia patients: role in improving thalassemia transfusion practice in Fayoum, Egypt. Transfusion. 2016;56(9):2303-7.
Ho H-K, Ha S-Y, Lam C-K, Chan GC, Lee T-L, Chiang AK, et al. Alloimmunization in Hong Kong southern Chinese transfusion-dependent thalassemia patients. Blood. 2001;97(12):3999-4000.
Winters JL, Pineda AA, Gorden LD, Bryant SC, Melton LJ, Vamvakas EC, et al. RBC alloantibody specificity and antigen potency in Olmsted County, Minnesota. Transfusion. 2001;41(11):1413-20.
Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh (D) incompatibility. Transfusion medicine reviews. 2003;17(1):57-68.
Mo Z, Li H, Huang L, Jiao W. Prevalence and specificity of RBC alloantibodies in the general hospitalised population in Guangxi. Transfusion Medicine. 2015;25(5):313-9.